JP2021501183A - 二環式のスルホン及びスルホキシド、並びにその使用方法 - Google Patents
二環式のスルホン及びスルホキシド、並びにその使用方法 Download PDFInfo
- Publication number
- JP2021501183A JP2021501183A JP2020524177A JP2020524177A JP2021501183A JP 2021501183 A JP2021501183 A JP 2021501183A JP 2020524177 A JP2020524177 A JP 2020524177A JP 2020524177 A JP2020524177 A JP 2020524177A JP 2021501183 A JP2021501183 A JP 2021501183A
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- pyrrolo
- triazole
- fluoro
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COC(C[C@@](c(cc1)cc(F)c1F)O*)=O Chemical compound COC(C[C@@](c(cc1)cc(F)c1F)O*)=O 0.000 description 2
- WBJBXWLZDZNZJW-RYUDHWBXSA-N CC(C)(C#N)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound CC(C)(C#N)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O WBJBXWLZDZNZJW-RYUDHWBXSA-N 0.000 description 1
- MWGGBZPAGIKAMH-QZSHFQNPSA-N CC(C)(C)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CC(C)(C)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O MWGGBZPAGIKAMH-QZSHFQNPSA-N 0.000 description 1
- GQVULWOGMBFQRZ-QVCLKMBOSA-N CC(CC=C1F)([C@H](C[C@@H](c2n3)F)[n]2nc3S([C@H](C2)[C@@H]2F)(=O)=O)C=C1F Chemical compound CC(CC=C1F)([C@H](C[C@@H](c2n3)F)[n]2nc3S([C@H](C2)[C@@H]2F)(=O)=O)C=C1F GQVULWOGMBFQRZ-QVCLKMBOSA-N 0.000 description 1
- UIBIFMBOTZIONB-UCBNGSGESA-N CC1([C@H](C[C@@H](c2n3)F)[n]2nc3S(C(CO)(F)F)(=O)=O)C=CC=CC1 Chemical compound CC1([C@H](C[C@@H](c2n3)F)[n]2nc3S(C(CO)(F)F)(=O)=O)C=CC=CC1 UIBIFMBOTZIONB-UCBNGSGESA-N 0.000 description 1
- MAWXMDLEICESPX-MSYFUGIWSA-N CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CCCCC(CC)COC(CCSc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O MAWXMDLEICESPX-MSYFUGIWSA-N 0.000 description 1
- RHYFAPSWWDTTHB-KBPBESRZSA-N CCOC(C1(CS(c2n[n]([C@@H](C[C@@H]3F)c4ccccc4)c3n2)(=O)=O)CC1)=O Chemical compound CCOC(C1(CS(c2n[n]([C@@H](C[C@@H]3F)c4ccccc4)c3n2)(=O)=O)CC1)=O RHYFAPSWWDTTHB-KBPBESRZSA-N 0.000 description 1
- ZPTKBGCSXKQXCO-ZOBORPQBSA-N CCOC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CCOC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O ZPTKBGCSXKQXCO-ZOBORPQBSA-N 0.000 description 1
- ZPTKBGCSXKQXCO-RFGFWPKPSA-N CCOC([C@H](C1)[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound CCOC([C@H](C1)[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O ZPTKBGCSXKQXCO-RFGFWPKPSA-N 0.000 description 1
- KTFGVGUADRGJGI-PTNGSMBKSA-N CCOC/C=C(\c1nc(Br)n[n]1C1OCCCC1)/c1ccccc1 Chemical compound CCOC/C=C(\c1nc(Br)n[n]1C1OCCCC1)/c1ccccc1 KTFGVGUADRGJGI-PTNGSMBKSA-N 0.000 description 1
- LJUZYKJUZIKFOS-IGHFXTMLSA-N C[C@@H](C1)c2nc(/S(/C(F)(F)F)=C\C)n[n]2[C@@H]1c(cccc1)c1Cl Chemical compound C[C@@H](C1)c2nc(/S(/C(F)(F)F)=C\C)n[n]2[C@@H]1c(cccc1)c1Cl LJUZYKJUZIKFOS-IGHFXTMLSA-N 0.000 description 1
- KHJCBTJJISKZPZ-IUCAKERBSA-N F[C@@H](C1)c2nc(S)n[n]2[C@@H]1c(cc1F)ccc1F Chemical compound F[C@@H](C1)c2nc(S)n[n]2[C@@H]1c(cc1F)ccc1F KHJCBTJJISKZPZ-IUCAKERBSA-N 0.000 description 1
- ZDELMEDCOLPGBI-RYUDHWBXSA-N F[C@@H](C1)c2nc(SC(C3)CC3(F)F)n[n]2[C@@H]1c1ccccc1 Chemical compound F[C@@H](C1)c2nc(SC(C3)CC3(F)F)n[n]2[C@@H]1c1ccccc1 ZDELMEDCOLPGBI-RYUDHWBXSA-N 0.000 description 1
- PSWSOAKNLQKMIW-VIFPVBQESA-N Fc1c([C@H](CCc2n3)[n]2nc3Br)cccc1 Chemical compound Fc1c([C@H](CCc2n3)[n]2nc3Br)cccc1 PSWSOAKNLQKMIW-VIFPVBQESA-N 0.000 description 1
- KDEZSZOJIGSNNQ-RYUDHWBXSA-N N#CC1(CC1)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound N#CC1(CC1)S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O KDEZSZOJIGSNNQ-RYUDHWBXSA-N 0.000 description 1
- AUBQCLBTOSVRQA-PYJNHQTQSA-N N#C[C@H](C1)C[C@@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O Chemical compound N#C[C@H](C1)C[C@@H]1S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(=O)=O AUBQCLBTOSVRQA-PYJNHQTQSA-N 0.000 description 1
- MGLDRWWWOALGNT-NOOOWODRSA-N NC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound NC([C@H](C1)[C@@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O MGLDRWWWOALGNT-NOOOWODRSA-N 0.000 description 1
- NTKDFUHUVGFVIL-UHFFFAOYSA-N O=C(c1nc(Br)n[n]1C1OCCCC1)c1ccccc1 Chemical compound O=C(c1nc(Br)n[n]1C1OCCCC1)c1ccccc1 NTKDFUHUVGFVIL-UHFFFAOYSA-N 0.000 description 1
- HWIUHIGUHUMVNA-IUCAKERBSA-N O=S(C(C(F)(F)F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O Chemical compound O=S(C(C(F)(F)F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)=O HWIUHIGUHUMVNA-IUCAKERBSA-N 0.000 description 1
- NOUKPAIFEWNYBL-DWBHSIJVSA-N O=S(C(C(F)(F)F)(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=S(C(C(F)(F)F)(F)F)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 NOUKPAIFEWNYBL-DWBHSIJVSA-N 0.000 description 1
- IQEFSLKSGODXCX-IUCAKERBSA-N O=S(C(F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3cc(I)ccc3)c2n1)=O Chemical compound O=S(C(F)(F)F)(c1n[n]([C@@H](C[C@@H]2F)c3cc(I)ccc3)c2n1)=O IQEFSLKSGODXCX-IUCAKERBSA-N 0.000 description 1
- JAVCKHCONFBHSN-QWRGUYRKSA-N O=S(C1CC1)(c1n[n]([C@@H](C[C@@H]2F)c(cccc3F)c3F)c2n1)=O Chemical compound O=S(C1CC1)(c1n[n]([C@@H](C[C@@H]2F)c(cccc3F)c3F)c2n1)=O JAVCKHCONFBHSN-QWRGUYRKSA-N 0.000 description 1
- PJZUHFWOIATBCJ-GJZGRUSLSA-N O=S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(c1ccccc1)=O Chemical compound O=S(c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1)(c1ccccc1)=O PJZUHFWOIATBCJ-GJZGRUSLSA-N 0.000 description 1
- UAONBOVYJRVWMR-FPVGNUTFSA-N O=[S@@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 Chemical compound O=[S@@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 UAONBOVYJRVWMR-FPVGNUTFSA-N 0.000 description 1
- MCHJBVZXWQWPKL-VUPYVKPUSA-N O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 Chemical compound O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 MCHJBVZXWQWPKL-VUPYVKPUSA-N 0.000 description 1
- TVWAKDKIJBAIGC-GJPGNPISSA-N O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=[S@@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 TVWAKDKIJBAIGC-GJPGNPISSA-N 0.000 description 1
- UAONBOVYJRVWMR-JLTPVHFHSA-N O=[S@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 Chemical compound O=[S@](C(F)F)c1n[n]([C@@H](CC2)c3cc(F)cc(F)c3)c2n1 UAONBOVYJRVWMR-JLTPVHFHSA-N 0.000 description 1
- MCHJBVZXWQWPKL-QDDONVENSA-N O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 Chemical compound O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c(cccc3)c3Cl)c2n1 MCHJBVZXWQWPKL-QDDONVENSA-N 0.000 description 1
- TVWAKDKIJBAIGC-ZPEMSAPTSA-N O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O=[S@](CF)c1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 TVWAKDKIJBAIGC-ZPEMSAPTSA-N 0.000 description 1
- LFUVVIZZBVWRKN-RNJOBUHISA-N O[C@H](C1)C[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 Chemical compound O[C@H](C1)C[C@H]1Sc1n[n]([C@@H](C[C@@H]2F)c3ccccc3)c2n1 LFUVVIZZBVWRKN-RNJOBUHISA-N 0.000 description 1
- DMDZWSRUOABYNL-DTWKUNHWSA-N O[C@H](C1)c2nc(Br)n[n]2[C@@H]1c(cc1)cc(F)c1F Chemical compound O[C@H](C1)c2nc(Br)n[n]2[C@@H]1c(cc1)cc(F)c1F DMDZWSRUOABYNL-DTWKUNHWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579392P | 2017-10-31 | 2017-10-31 | |
| US62/579,392 | 2017-10-31 | ||
| PCT/EP2018/079772 WO2019086494A1 (en) | 2017-10-31 | 2018-10-30 | Bicyclic sulfones and sulfoxides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501183A true JP2021501183A (ja) | 2021-01-14 |
| JP2021501183A5 JP2021501183A5 (enExample) | 2021-12-09 |
Family
ID=64051580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524177A Pending JP2021501183A (ja) | 2017-10-31 | 2018-10-30 | 二環式のスルホン及びスルホキシド、並びにその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11072617B2 (enExample) |
| EP (1) | EP3704097B1 (enExample) |
| JP (1) | JP2021501183A (enExample) |
| KR (1) | KR20200083515A (enExample) |
| CN (1) | CN111278809B (enExample) |
| AR (1) | AR113811A1 (enExample) |
| AU (1) | AU2018360270A1 (enExample) |
| BR (1) | BR112020008446A2 (enExample) |
| CA (1) | CA3078688A1 (enExample) |
| CL (1) | CL2020001062A1 (enExample) |
| CO (1) | CO2020003475A2 (enExample) |
| CR (1) | CR20200168A (enExample) |
| IL (1) | IL273847A (enExample) |
| MA (1) | MA50503A (enExample) |
| MX (1) | MX2020003451A (enExample) |
| PE (1) | PE20211247A1 (enExample) |
| PH (1) | PH12020550537A1 (enExample) |
| RU (1) | RU2020115915A (enExample) |
| SG (1) | SG11202002877RA (enExample) |
| TW (1) | TW201922748A (enExample) |
| WO (1) | WO2019086494A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110282A1 (es) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| CA3185865A1 (en) | 2017-07-14 | 2019-01-17 | F. Hoffmann-La Roche Ag | Bicyclic ketone compounds and methods of use thereof |
| KR20200083515A (ko) | 2017-10-31 | 2020-07-08 | 에프. 호프만-라 로슈 아게 | 2고리 설폰 및 설폭사이드, 및 이의 사용 방법 |
| JP7585205B2 (ja) | 2019-01-11 | 2024-11-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式ピロロトリアゾールケトン化合物及びその使用方法 |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| WO2023083847A1 (en) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines as ripk1 inhibitors and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR94123E (fr) * | 1965-07-23 | 1969-07-04 | Thomae Gmbh Dr K | Procédés pour fabriquer de nouvelles 4,5,6,7-tétrahydro-thiazolo[5,4-c]pyridines. |
| JPS62258385A (ja) * | 1986-04-30 | 1987-11-10 | シエ−リング・アグロケミカルズ・リミテツド | 除草剤 |
| WO2017004500A1 (en) * | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
| WO2017096301A1 (en) * | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| WO2017136727A2 (en) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3948903A (en) | 1972-12-15 | 1976-04-06 | Parke, Davis & Company | Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| DE69328430T2 (de) | 1992-07-27 | 2001-01-25 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Zielgerichte liposome zur blut-hirne schranke |
| US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| AU8071698A (en) | 1997-06-13 | 1998-12-30 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction |
| EP1254115A2 (en) | 2000-02-11 | 2002-11-06 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| JP4202250B2 (ja) | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| AU2003265585B2 (en) | 2002-08-26 | 2008-07-03 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| CN101284136A (zh) | 2002-12-03 | 2008-10-15 | 布朗歇特洛克菲勒神经科学研究所 | 传输物质穿过血脑屏障的人工低密度脂蛋白载体 |
| CA2524269A1 (en) | 2003-05-02 | 2004-11-18 | Elan Pharmaceuticals, Inc. | 4- bromo - 5 - (2- chloro - benzoylamino) - 1h - pyrazole - 3 - carboxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| EP2083009A1 (de) | 2008-01-22 | 2009-07-29 | Grünenthal GmbH | Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CN101824036A (zh) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用 |
| KR20140096100A (ko) | 2011-11-03 | 2014-08-04 | 에프. 호프만-라 로슈 아게 | 이환 피페라진 화합물 |
| CA2871695A1 (en) | 2012-05-22 | 2013-11-28 | F. Hoffmann-La Roche Ag | Substituted dipyridylamines and uses thereof |
| TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | ３－取代吡唑及其用途 |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| CN105164114B (zh) | 2013-05-01 | 2018-03-23 | 豪夫迈·罗氏有限公司 | C‑连接的杂环烷基取代的嘧啶类和它们的用途 |
| MA42164B1 (fr) | 2013-05-01 | 2019-12-31 | Hoffmann La Roche | Composes biheteroaryle et leurs utilisations |
| RU2741810C2 (ru) | 2013-07-10 | 2021-01-28 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды конденсированного пиперидина в качестве модуляторов ионных каналов |
| MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
| PE20161223A1 (es) | 2014-03-26 | 2016-11-12 | Hoffmann La Roche | Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| CN107406462B (zh) | 2015-03-09 | 2020-11-10 | 豪夫迈·罗氏有限公司 | 三环dlk抑制剂及其用途 |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| US10751444B2 (en) | 2015-08-07 | 2020-08-25 | Victor Matthew Phillips | Flowable hemostatic gel composition and its methods of use |
| US10961258B2 (en) * | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN110267949A (zh) | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
| AR110282A1 (es) | 2016-12-02 | 2019-03-13 | Hoffmann La Roche | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CA3185865A1 (en) | 2017-07-14 | 2019-01-17 | F. Hoffmann-La Roche Ag | Bicyclic ketone compounds and methods of use thereof |
| WO2019072942A1 (en) | 2017-10-11 | 2019-04-18 | F. Hoffmann-La Roche Ag | BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1 |
| KR20200083515A (ko) | 2017-10-31 | 2020-07-08 | 에프. 호프만-라 로슈 아게 | 2고리 설폰 및 설폭사이드, 및 이의 사용 방법 |
-
2018
- 2018-10-30 KR KR1020207015138A patent/KR20200083515A/ko not_active Ceased
- 2018-10-30 CN CN201880070578.0A patent/CN111278809B/zh active Active
- 2018-10-30 EP EP18796020.8A patent/EP3704097B1/en active Active
- 2018-10-30 JP JP2020524177A patent/JP2021501183A/ja active Pending
- 2018-10-30 US US16/175,206 patent/US11072617B2/en active Active
- 2018-10-30 BR BR112020008446-8A patent/BR112020008446A2/pt not_active Application Discontinuation
- 2018-10-30 CA CA3078688A patent/CA3078688A1/en active Pending
- 2018-10-30 PE PE2020000353A patent/PE20211247A1/es unknown
- 2018-10-30 WO PCT/EP2018/079772 patent/WO2019086494A1/en not_active Ceased
- 2018-10-30 TW TW107138469A patent/TW201922748A/zh unknown
- 2018-10-30 CR CR20200168A patent/CR20200168A/es unknown
- 2018-10-30 RU RU2020115915A patent/RU2020115915A/ru unknown
- 2018-10-30 AU AU2018360270A patent/AU2018360270A1/en not_active Abandoned
- 2018-10-30 SG SG11202002877RA patent/SG11202002877RA/en unknown
- 2018-10-30 MA MA050503A patent/MA50503A/fr unknown
- 2018-10-30 MX MX2020003451A patent/MX2020003451A/es unknown
- 2018-10-30 AR ARP180103157A patent/AR113811A1/es unknown
-
2020
- 2020-03-25 CO CONC2020/0003475A patent/CO2020003475A2/es unknown
- 2020-04-06 IL IL273847A patent/IL273847A/en unknown
- 2020-04-20 CL CL2020001062A patent/CL2020001062A1/es unknown
- 2020-04-30 PH PH12020550537A patent/PH12020550537A1/en unknown
-
2021
- 2021-06-06 US US17/340,082 patent/US12338241B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR94123E (fr) * | 1965-07-23 | 1969-07-04 | Thomae Gmbh Dr K | Procédés pour fabriquer de nouvelles 4,5,6,7-tétrahydro-thiazolo[5,4-c]pyridines. |
| JPS62258385A (ja) * | 1986-04-30 | 1987-11-10 | シエ−リング・アグロケミカルズ・リミテツド | 除草剤 |
| WO2017004500A1 (en) * | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
| WO2017096301A1 (en) * | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| WO2017136727A2 (en) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
Non-Patent Citations (3)
| Title |
|---|
| LIPSON, V. V. ET AL.: "Reactions of 3-amino-1,2,4-triazoles with cinnamic aldehydes", RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION, vol. 58, no. 7, JPN6022041590, 2009, pages 1 - 4, ISSN: 0005052082 * |
| REGISTRY[ONLINE], JPN7022004672, ISSN: 0005052084 * |
| WALY, M. A. ET AL.: "A novel synthesis of imidazo[4,5-d]azepine ring system", POLISH J. CHEM., vol. 70, JPN6022041592, 1996, pages 296 - 301, ISSN: 0005052083 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018360270A1 (en) | 2020-03-26 |
| PE20211247A1 (es) | 2021-07-13 |
| CN111278809B (zh) | 2024-06-25 |
| EP3704097A1 (en) | 2020-09-09 |
| KR20200083515A (ko) | 2020-07-08 |
| RU2020115915A (ru) | 2021-12-01 |
| US11072617B2 (en) | 2021-07-27 |
| BR112020008446A2 (pt) | 2020-12-29 |
| US20230002391A1 (en) | 2023-01-05 |
| EP3704097B1 (en) | 2023-10-25 |
| MX2020003451A (es) | 2020-08-03 |
| MA50503A (fr) | 2020-09-09 |
| AR113811A1 (es) | 2020-06-10 |
| IL273847A (en) | 2020-05-31 |
| TW201922748A (zh) | 2019-06-16 |
| US20190127382A1 (en) | 2019-05-02 |
| SG11202002877RA (en) | 2020-04-29 |
| CL2020001062A1 (es) | 2020-08-21 |
| US12338241B2 (en) | 2025-06-24 |
| WO2019086494A1 (en) | 2019-05-09 |
| CO2020003475A2 (es) | 2020-04-24 |
| CN111278809A (zh) | 2020-06-12 |
| CA3078688A1 (en) | 2019-05-09 |
| PH12020550537A1 (en) | 2021-03-22 |
| CR20200168A (es) | 2020-07-12 |
| RU2020115915A3 (enExample) | 2022-05-06 |
| EP3704097C0 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398391B2 (ja) | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 | |
| JP7734163B2 (ja) | 二環式ケトン化合物及びその使用方法 | |
| US12338241B2 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| JP6890179B2 (ja) | 二環式アミド化合物及びその使用方法 | |
| JP7362600B2 (ja) | Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物 | |
| US20250282788A1 (en) | Bicyclic ketone compounds and methods of use thereof | |
| RU2797922C2 (ru) | Бициклические кетоны и способы их применения | |
| HK40024493B (zh) | 二环碸类和亚碸类、以及其使用方法 | |
| HK40024493A (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| HK40062362B (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40062362A (en) | Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof | |
| HK40036919A (en) | Compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211027 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211027 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220929 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230509 |